USFDA inspects contract manufacturing facility of Jubilant Pharmova at Montreal Canada
The US FDA in its communication mentioned it may withhold approval of any pending applications or supplements in which this facility is listed.
The US FDA in its communication mentioned it may withhold approval of any pending applications or supplements in which this facility is listed.
The company has reported total income of Rs. 1682.45 crores during the period ended March 31, 2023
This loan is in addition to earlier announced CAD 25 million loan committed by the Province of Quebec
Based on this inspection and the USFDA VAI classification, this facility is in compliance with regard to current good manufacturing practices (cGMP)
The Tc 99m Mertiatide Injection is used in the diagnosis of congenital and acquired renal abnormalities
The company will submit an action plan on the observations and will engage with US FDA for next steps.
The company currently supplies one product to the US market that contributes low- single digit revenue to Jubilant Pharmova revenue
The company has reported total income of Rs. 1612.60 crores during the period ended September 30, 2022.
He has over two decades of rich experience in management consulting, advising and transforming leading generic pharmaceutical companies in India and global markets
With the receipt of the EIR, the inspection stands successfully closed.
Subscribe To Our Newsletter & Stay Updated